Avri Ben-Ze'ev studied at the Hebrew University of Jerusalem, where he received a Ph.D. degree in virology in 1977. After conducting postdoctoral research at the Massachusetts Institute of Technology, he joined the staff of the Weizmann Institute of Science in 1979. He was promoted to an Associate Professor in 1985 and a Full Professor in 1999. Now, he is a Member of the Molecular Cell Biology Department, and he has been a Visiting Professor at Harvard University Medical School, Boston University Medical School, The Burnham Institute in La Jolla, The Curie Institute in Paris, and The Albert Einstein College of Medicine. He is a member of several Israeli, American, and international professional societies, including the American Society for Cell Biology, the American Association for Cancer Research, the Israel Society for Cell Biology and Molecular Biology, the New York Academy of Sciences, and the International Agency Against Cancer (UICC), and serves as an Executive Editor of Molecular and Cellular Differentiation, as an Editor of the Journal of Cellular Biochemistry, and as a Panel Member of the Molecular Oncology Program of the Swiss National Science Foundation. Professor Ben-Ze'ev studies genes and cellular mechanisms involved in cancer development. His research focuses on beta-catenin, a gene playing a dual role in cell adhesion and transcription. Ben-Ze'ev has clarified what are the consequences of beta-catenin hyperactivation in cancerous cells, and identified some of the signals unleashed by this gene in malignancy. These studies could help design genetically-based screening for early-stage colon cancer and develop target-specific therapy to prevent, or reverse, the metastatic spread of tumors.
Biography Updated on 21 May 2008